Mezagitamab ( DrugBank: Mezagitamab )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 63 | Idiopathic thrombocytopenic purpura | 1 |
| 66 | IgA nephropathy | 2 |
63. Idiopathic thrombocytopenic purpura
Clinical trials : 391 / Drugs : 235 - (DrugBank : 50) / Drug target genes : 49 - Drug target pathways : 139
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2019-004103-12-BG (EUCTR) | 15/12/2020 | 22/06/2020 | A Study to Evaluate Safety, Tolerability and Efficacy of TAK-079 in Patients with Immune Thrombocytopenia | A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability and Efficacy of TAK-079 in Patients with Persistent/Chronic Primary Immune Thrombocytopenia | Primary immune thrombocytopenia MedDRA version: 23.0;Level: LLT;Classification code 10050245;Term: Autoimmune thrombocytopenia;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] | Product Name: TAK-079 Product Code: TAK-079 INN or Proposed INN: Mezagitamab Other descriptive name: TAK-079 | Takeda Development Center Americas, Inc. (Takeda) | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 54 | Phase 2 | United States;Slovenia;Greece;Spain;Ukraine;Croatia;Bulgaria;Germany;Italy;Japan;China |
66. IgA nephropathy
Clinical trials : 275 / Drugs : 258 - (DrugBank : 82) / Drug target genes : 36 - Drug target pathways : 140
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05174221 (ClinicalTrials.gov) | November 9, 2022 | 14/12/2021 | A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy | A Phase 1b, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Mezagitamab (TAK-079) in Patients With Primary IgA Nephropathy in Combination With Stable Background Therapy | Kidney Disease | Drug: Mezagitamab | Takeda | NULL | Recruiting | 18 Years | N/A | All | 16 | Phase 1 | United States;Australia;Belgium;China;Hungary;Italy;Japan;Korea, Republic of;Serbia;Singapore;Spain;Taiwan;United Kingdom |
| 2 | JPRN-jRCT2011220009 | 17/07/2022 | 15/06/2022 | A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy | A Phase 1b, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Mezagitamab (TAK-079) in Patients With Primary IgA Nephropathy in Combination With Stable Background Therapy | Kidney Disease | TAK-079 (Mezagitamab) Mezagitamab, subcutaneous injection, once weekly for 8 weeks then once every 2 weeks for 16 weeks in the Main Study. Same dosing regimen will be repeated in LTE Retreatment Period. | Nishizawa Atsushi | NULL | Recruiting | >= 18age old | Not applicable | Both | 16 | Phase 1 | Australia;China;Spain;Italy;South Korea;Serbia;Singapore;Taiwan;USA;Belgium;Hungary;UK;Japan |